Figure 3.

Sclerostin inhibits mineralization induced by GSK3 inhibition in C3H10T1/2 cells. (a) Quantification of matrix mineralization evaluated by Alizarin Red-S staining of C3H10T1/2 cells incubated with either vehicle, 20% Wnt3a-conditioned medium, 25 ng ml⁻¹ BMP2 or 10 μM SB216763 (a selective GSK3 inhibitor), with or without 10 μg ml⁻¹ sclerostin. (b) Quantification of matrix mineralization by C3H10T1/2 cells incubated with 10 μM SB216763 or its vehicle, in the presence of various doses of sclerostin. *P<0.01 for Wnt3a, BMP2 or SB216763 versus their vehicle; +P<0.01 for SOST versus its vehicle.